Intermediatebiotechnology

Gene Therapy

Overview

Gene therapy treats disease by delivering genetic material: replacing defective genes (Luxturna for RPE65 blindness), adding functional copies (Zolgensma for SMA), or editing in place (Casgevy). Vectors include AAV (non-integrating, tissue-tropic serotypes), lentiviruses (integrating, ex vivo), and lipid nanoparticles (mRNA). After early setbacks (1999 Gelsinger tragedy), the field now has 10+ approved products.

Learning objectives

  • Define gene therapy strategies
  • Compare AAV, lentiviral, and LNP delivery
  • Name approved therapies and their mechanisms
  • Describe safety lessons and challenges

Strategies

Gene replacement/addition: deliver a working copy (doesn't remove the mutant). Gene editing: correct in place (CRISPR). Gene silencing: shRNA/siRNA knockdown. Cell therapies (CAR-T) engineer cells with new genes: sometimes classed separately, mechanistically gene therapy.

Add, correct, or silence

Three strategies cover most monogenic diseases and beyond.

Delivery vehicles

AAV: small (~4.7 kb capacity), non-integrating, serotypes target liver/eye/muscle/CNS; pre-existing immunity limits redosing. Lentivirus: integrates (stable, ex vivo HSC therapies like betibeglogene). LNPs: deliver mRNA transiently (COVID vaccines proved the platform; in vivo CRISPR via LNP in trials).

AAV's size limit

4.7 kb capsids exclude big genes (dystrophin needs mini-versions): packaging constrains design.

Approved therapies

Luxturna (2017): AAV-RPE65 for inherited blindness. Zolgensma: AAV-SMN1 for spinal muscular atrophy (~$2M, one-time). Hemgenix/Roctavian: hemophilia A/B. Casgevy/Lyfgenia: sickle cell. CAR-Ts (Kymriah, Yescarta): engineered T cells curing some leukemias/lymphomas.

Prices and access

Million-dollar one-time prices strain health systems: cures exist that societies can't afford to deliver.

Safety lessons

1999: Jesse Gelsinger died from adenoviral vector immune response, freezing the field. Early retroviral trials caused leukemia via insertional mutagenesis. Modern designs (self-inactivating lentiviruses, tissue-specific AAV) reflect hard-won caution; long-term follow-up is mandatory.

Caution earned

Each tragedy rewrote vector design: the field's safety culture was built from failures.

Key points

  • Strategies: gene addition, editing, silencing
  • AAV (in vivo, non-integrating), lentivirus (ex vivo, integrating), LNP (mRNA)
  • Approved: Luxturna, Zolgensma, hemophilia therapies, Casgevy, CAR-Ts
  • Safety shaped by Gelsinger tragedy and insertional mutagenesis cases

Common misconceptions

✗ Myth: Gene therapy changes inherited DNA for all descendants.

✓ Truth: Approved therapies are somatic (or ex vivo); germline editing is not practiced or permitted.

✗ Myth: One dose cures permanently, guaranteed.

✓ Truth: Durability varies; AAV expression can wane, and long-term data are still maturing.

Practice questions

Q1. Luxturna treats inherited blindness by
  1. Editing the germline
  2. AAV delivery of functional RPE65 to retinal cells
  3. Corneal transplant
  4. Laser surgery
Answer: B.

Subretinal AAV supplies the missing enzyme in RPE cells.

Q2. AAV vectors are favored for in vivo therapy because they
  1. Integrate efficiently
  2. Are mostly non-integrating with tissue-specific serotypes
  3. Carry huge genes
  4. Avoid immunity
Answer: B.

Episomal persistence without integration; serotypes target tissues.

Q3. The 1999 Gelsinger tragedy involved
  1. CRISPR
  2. A fatal immune response to an adenoviral vector
  3. Cloning
  4. Vaccines
Answer: B.

Ornithine transcarbamylase trial: vector immunity caused multi-organ failure.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why is SMA treatable by gene therapy?

Single-gene (SMN1) loss with a backup gene (SMN2): adding SMN1 via AAV rescues motor neurons if treated early.

What limits AAV redosing?

Neutralizing antibodies from the first dose (or natural AAV exposure) block repeat administration.

How do CAR-T cells work?

Patient T cells are lentivirally engineered with chimeric antigen receptors targeting cancer, then reinfused.